Genzyme, a Sanofi Company
Genzyme, a Sanofi Company
Explore linked clinical trials.22 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Not stated | 2026-10-05 | NCT07582276 | |
| Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-09-16 | NCT04883242 | |
| Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder | Active, not recruiting | Phase 4 | 2026-09-09 | NCT05164055 | |
| Developing a Management Approach for Patients With "Late-Onset" Pompe Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder | Active, not recruiting | Not stated | 2026-09-03 | NCT03694561 | |
| ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Small Vessel Diseases, Ceroid Lipofuscinosis, Neuronal, 2, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Fabry disease, GM1 gangliosidosis, Gangliosidoses, Gaucher disease, Hemic and Lymphatic Diseases, Hereditary Central Nervous System Demyelinating Diseases, Infant, Newborn, Diseases, Leukoencephalopathies, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Mucopolysaccharidosis III, Neurobehavioral Manifestations, Neurologic Manifestations, Niemann-Pick disease, Niemann-Pick disease type C, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, Skin and Connective Tissue Diseases, Sulfatidosis, Wolman disease, X-linked disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrotendinous xanthomatosis, cerebrovascular disorder, cholesteryl ester storage disease, connective tissue disorder, cutaneous mucinosis, demyelinating disease, hereditary disease, histiocytosis, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, lymphatic system disorder, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, metachromatic leukodystrophy, mucopolysaccharidosis, mucopolysaccharidosis type 2, mucopolysaccharidosis type 4, mucopolysaccharidosis type 6, mucopolysaccharidosis type 7, nervous system disorder, non-Langerhans cell histiocytosis, sphingolipidosis, vascular disorder, xanthomatosis | Enrolling by invitation | Not stated | 2026-07-28 | NCT05368038 | |
| Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-07-23 | NCT05346809 | |
| Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance | Blood Protein Disorders, Hemic and Lymphatic Diseases, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy | Active, not recruiting | Phase 2 | 2026-07-23 | NCT04614558 | |
| Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Gaucher Disease, Type 1, Gaucher Disease, Type 3, Gaucher disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis | Active, not recruiting | Phase 2 | 2026-07-10 | NCT02843035 | |
| Pompe Disease Registry Protocol | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder | Recruiting | Not stated | 2026-06-23 | NCT00231400 | |
| Fabry Disease Registry & Pregnancy Sub-registry | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fabry disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, X-linked disease, angiokeratoma, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, neoplasm, nervous system disorder, sphingolipidosis, vascular cancer, vascular disorder | Recruiting | Not stated | 2026-06-23 | NCT00196742 | |
| Isa-Pom-Dex in Elderly/Frail Subjects With RRMM | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-06-09 | NCT05911321 | |
| Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cancer, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-06-02 | NCT05145400 | |
| Pompe Pregnancy Sub-Registry | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder | Recruiting | Not stated | 2026-04-16 | NCT00567073 | |
| International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Gaucher disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, nervous system disorder, sphingolipidosis | Recruiting | Not stated | 2026-04-14 | NCT00358943 | |
| Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder | Recruiting | Not stated | 2026-04-08 | NCT01665326 | |
| China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder | Recruiting | Phase 4 | 2026-03-23 | NCT06666413 | |
| Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-03-12 | NCT05401786 | |
| A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa | Glycogen Storage Disease Type II-Pompe's Disease | Active, not recruiting | Phase 2 | 2026-01-30 | NCT03019406 | |
| The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients | Heart Transplantation | Enrolling by invitation | Phase 2 | 2026-01-14 | NCT03292861 | |
| Glucose Consumption in MS Using [F-18]FDG-PET | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 4 | 2026-01-09 | NCT07087106 | |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Recruiting | Phase 2 | 2025-12-04 | NCT06121180 | |
| Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Not applicable | 2025-04-03 | NCT06068582 |